^
BIOMARKER:
PD-L1 overexpression
i
Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
Entrez ID:
Related biomarkers:
PD-L1 overexpression
NSCLC
pembrolizumab
Sensitive
:
A2
J Clin Oncol - 2wk
PD-L1 overexpression
Thyroid Gland Anaplastic Carcinoma
anlotinib + sintilimab
Sensitive
:
C4
Onco Targets Ther - 2wk
PD-L1 overexpression
Lung Non-Squamous Non-Small Cell Cancer
Immunotherapy
Sensitive
:
C3
Lung Cancer - 3wk
PD-L1 overexpression
NSCLC
cemiplimab
Sensitive
:
C1
PD-L1 overexpression
NSCLC
atezolizumab
Sensitive
:
C1
PD-L1 overexpression
Urothelial Cancer
tislelizumab
Sensitive
:
C1
PD-L1 overexpression
Lung Non-Squamous Non-Small Cell Cancer
pembrolizumab
Sensitive
:
A2
PD-L1 overexpression
NSCLC
bevacizumab + atezolizumab
Sensitive
:
A2
PD-L1 overexpression
NSCLC
bevacizumab
Sensitive
:
A2
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
atezolizumab
Sensitive
:
C1
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
pembrolizumab
Sensitive
:
A2
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
nivolumab + ipilimumab
Sensitive
:
A2
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
cemiplimab
Sensitive
:
C1
PD-L1 overexpression
NSCLC
atezolizumab + MTIG7192A
Sensitive
:
B
PD-L1 overexpression
NSCLC
carboplatin + albumin-bound paclitaxel
Sensitive
:
B
PD-L1 overexpression
NSCLC
carboplatin + gemcitabine
Sensitive
:
B
PD-L1 overexpression
NSCLC
cisplatin + albumin-bound paclitaxel
Sensitive
:
B
PD-L1 overexpression
NSCLC
GC
Sensitive
:
B
PD-L1 overexpression
NSCLC
carboplatin + pemetrexed
Sensitive
:
B
PD-L1 overexpression
NSCLC
cisplatin + pemetrexed
Sensitive
:
B
PD-L1 overexpression
GastroEsophageal Cancer
PD1 inhibitor
Sensitive
:
B
PD-L1 overexpression
GastroEsophageal Cancer
PD-L1 inhibitor
Sensitive
:
B
PD-L1 overexpression
Triple Negative Breast Cancer
pembrolizumab
Sensitive
:
B
PD-L1 overexpression
NSCLC
tislelizumab
Sensitive
:
C1
PD-L1 overexpression
Urothelial Cancer
durvalumab
Sensitive
:
B
PD-L1 overexpression
NSCLC
nivolumab
Sensitive
:
B
PD-L1 overexpression
NSCLC
avelumab
Sensitive
:
B
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our